Skip to content

A Trial to Assess the Influence of a Pictorial Medication Calendar on Medication Taking Behaviour

A Randomized Controlled Trial to Assess the Influence of a Picture-Based Antiemetic Medication Calendar on Medication-Taking Behavior in Adults Receiving Chemotherapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04701736
Enrollment
70
Registered
2021-01-08
Start date
2017-01-31
Completion date
2018-01-31
Last updated
2021-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Chemotherapy, Medication Adherence

Keywords

patient adherence, chemotherapy, pictorial aid, complex medication regimen, cancer

Brief summary

Determine if an oncology pictorial medication calendar will improve patient adherence to oncology supportive care medication regimens for adult patients receiving adjuvant or neo-adjuvant chemotherapy treatment for cancer.

Detailed description

Primary Objective: In order to evaluate the impact of such an approach on adherence, a prospective, open-label, randomized controlled pilot trial (RCT) was carried out to determine if a picture-based medication calendar would improve patient adherence to antiemetic medication regimens for adult patients receiving chemotherapy treatment for solid organ tumor origins. The secondary objectives were: 1) to assess medication use and self-efficacy parameters, 2) to determine patient comfort with antiemetic regimen prescribed along with chemotherapy and 3) to determine patient satisfaction with the calendar study tool.

Interventions

DEVICEPicture Medication Calendar

Sponsors

University of Waterloo
CollaboratorOTHER
Medbuy Corporation
CollaboratorUNKNOWN
London Health Sciences Centre
CollaboratorOTHER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Outpatients 18 years or older receiving chemotherapy treatment for neoadjuvant or adjuvant solid organ cancers, * Able to provide consent for themselves, * Calendar was only available in the English language, thus fluency in English was required.

Exclusion criteria

* Participants who did not attain a minimum of grade 8 education, * Significant visual impairment that precluded the ability to read the picture-based medication calendar, * Difficulty swallowing with requirement for liquid formulations of medications, * If planned to receive multiple cycles of chemotherapy at satellite oncology location instead of main study site, * If unable to repeat the instructions back to research personnel or a care provider had to speak on the participant's behalf, the participant was withdrawn from the study.

Design outcomes

Primary

MeasureTime frameDescription
Medication Adherence to Prescribed Antiemetics1 yearAdherence is quantified as the number of doses taken of a prescribed agent divided by the number of doses prescribed, expressed as a percentage. Pill counts were utilized to calculate the number of missed doses or pills taken as a percentage of the total number prescribed and dispensed.

Secondary

MeasureTime frameDescription
Patient Understanding and Satisfaction Survey1 yearThe participant survey conducted at end of study was investigator-created and asked questions regarding demographics and medication taking behaviors. Questions specifically related to the calendar for those in the intervention arm were also asked. Questions regarding satisfaction with the calendar as well as complexity of medication regimen for oncologic treatment were assessed using a 5-point Likert scale.
Medication Use and Self-Efficacy (MUSE) Scale1 year19 The tool measures an individual's perceived ability to understand information about prescribed medicines, and to follow instructions for use.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026